GT Biopharma, Inc. - Common Stock (GTBP) Institutional Ownership

13F Institutional Holders and Ownership History from Q4 2023 to Q4 2025

Type / Class
Equity / Common Stock
Symbol
GTBP on Nasdaq
Shares outstanding
3,148,458
Price per share
$0.79
All holders as of 30 Sep 2025
Q3 2025
Total 13F shares
374,216
Total reported value
$222,177
% of total 13F portfolios
0%
Share change
+175,541
Value change
+$22,238
Number of holders
20
Reported Shares, Excluding Options vs Price
Reported Value, Excluding Options
Total Investors

Significant Owners of GT Biopharma, Inc. - Common Stock (GTBP) based on Schedule 13D/G filings

Filer Ownership Change % Holdings Value Net Change Nb Shares Change % Reporting Name Report Period
Five Narrow Lane LP 10% $567,589 253,388 Five Narrow Lane LP 13 May 2025
CYTOVANCE BIOLOGICS INC 9.8% $491,584 219,457 CYTOVANCE BIOLOGICS INC 30 Sep 2024
BRISTOL INVESTMENT FUND LTD 2.4% $171,405 74,524 Bristol Investment Fund, Ltd. 29 May 2025

As of 30 Sep 2025, 20 institutional investors reported holding 374,216 shares of GT Biopharma, Inc. - Common Stock (GTBP). This represents 12% of the company’s total 3,148,458 outstanding shares.

Top 25 Institutional Shareholders

The largest institutional shareholders of GT Biopharma, Inc. - Common Stock (GTBP) together control 12% of the company’s outstanding shares — a level of ownership often associated with strong institutional conviction and long‑term capital commitment.

Institution Ownership % Shares Held Share Change % Portfolio % Holdings Value
DRW Securities, LLC 4.5% 142,380 0% $83,505
BANK OF MONTREAL /CAN/ 2.9% 92,530 0% 0% $54,593
CITADEL ADVISORS LLC 1.3% 39,633 0% $23,562
GEODE CAPITAL MANAGEMENT, LLC 0.76% 23,966 +0.54% 0% $14,250
TWO SIGMA SECURITIES, LLC 0.54% 17,065 0% $10,009
MORGAN STANLEY 0.45% 14,015 +249% 0% $8,220
VANGUARD GROUP INC 0.33% 10,504 0% 0% $6,250
WELLS FARGO & COMPANY/MN 0.32% 10,012 0% 0% $5,872
BlackRock, Inc. 0.31% 9,737 0% 0% $5,711
OSAIC HOLDINGS, INC. 0.16% 5,073 -56% 0% $4,695
Newbridge Financial Services Group, Inc. 0.12% 3,750 +36% 0% $2,199
UBS Group AG 0.08% 2,626 -55% 0% $1,541
Tower Research Capital LLC (TRC) 0.05% 1,704 +279% 0% $999
Clearstead Advisors, LLC 0.03% 865 0% 0% $508
JONES FINANCIAL COMPANIES LLLP 0.01% 300 0% 0% $230
BANK OF AMERICA CORP /DE/ 0% 24 -17% 0% $14
BNP PARIBAS FINANCIAL MARKETS 0% 16 0% 0% $9
BLUE BELL PRIVATE WEALTH MANAGEMENT, LLC 0% 10 0% 0% $6
SBI Securities Co., Ltd. 0% 5 -17% 0% $3
JPMORGAN CHASE & CO 0% 1 0% 0% $1
Front Row Advisors LLC 0% 0 -100% $0
RENAISSANCE TECHNOLOGIES LLC 0% 0 -100% $0
ELEVATION POINT WEALTH PARTNERS, LLC 0% 0 -100% $0
JPMORGAN CHASE & CO 0% 1 0% $1
Allworth Financial LP 0% 1 0% $1

Institutional Holders of GT Biopharma, Inc. - Common Stock (GTBP) across Reporting Periods

Period Reported Shares, Excl. Options Value, Excl. Options Value Change Price (Median) Investors
2025 Q4 70,644 $52,830 +$49,885 $0.79 5
2025 Q3 374,216 $222,177 +$22,238 $0.59 20
2025 Q2 198,676 $711,263 +$381,371 $3.58 21
2025 Q1 99,688 $220,497 -$29,000,898 $2.15 20
2024 Q4 1,242,247 $29,289,518 -$3,837 $3.05 18
2024 Q3 1,246,007 $35,300,829 +$5,339,747 $2.31 15
2024 Q2 1,080,160 $38,124,773 +$37,881,741 $2.83 16
2024 Q1 277 $1,226 +$10 $4.40 3
2023 Q4 208 $53 +$53 $0.26 2